Hikma Pharmaceuticals PLC announced that Dr. Bill Larkins has been appointed President of its Injectables business, effective 1 September 2023. Bill will be based in the US and report to Riad Mishlawi in his new role as Hikma's Chief Executive Officer. Bill has extensive experience in the sterile injectable generic market.

He was previously Chief Executive Officer of Custopharm, which was acquired by Hikma in 2022 and has since been Hikma´s Senior Vice President, R&D, Injectables. During his career, Bill has held senior leadership roles at leading injectable pharmaceutical companies including Bedford Laboratories and ESI Lederle/Baxter. He also played a significant role at Schein Pharmaceuticals' Steris Laboratories in Phoenix and at Amylin Pharmaceuticals, where he worked on the development of complex injectable medicines.